Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Precision medicine in hematological oncology: development to the present day

Tariq Mughal • 25 Feb 2019
ISAL 2019
Chronic Myeloid Leukemia General Leukemia Imatinib

Tariq Mughal, MD, MB, BS, MRCS, MRCP, FRCP, of Tufts University School of Medicine, Boston, MA, gives us a comprehensive background of the devlopment of precision medicine in the field of hematological oncology. Starting with the case of imatinib in chronic myeloid leukemia (CML), he takes us through to the present day. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Tariq Mughal

Combination therapies in MPNs and the potential for personalizing medicine using genomic profiling
5:20
Combination therapies in MPNs and the potential for personalizing medicine using genomic profiling
Tariq Mughal • 30 Oct 2024
Important topics from the MPN Congress 2024: addressing the risk of transformation to acute leukemia
9:34
Important topics from the MPN Congress 2024: addressing the risk of transformation to acute leukemia
Tariq Mughal • 30 Oct 2024
Updates in PV treatment: the efficacy of ropeginterferon alfa-2b
6:05
Updates in PV treatment: the efficacy of ropeginterferon alfa-2b
Tariq Mughal • 30 Oct 2024
Acute leukemias: the doubled-edged sword of genetic complexity
4:23
Acute leukemias: the doubled-edged sword of genetic complexity
Tariq Mughal • 25 Feb 2019

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals